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Patient participation in treatment decision-making is being increasingly advocated, although cancer treatments are often guideline-
driven. Trade-offs between benefits and side effects underlying guidelines are made by clinicians. Evidence suggests that clinicians are
inaccurate at predicting patient values. The aim was to assess what role oncologists and cancer patients prefer in deciding about
treatment, and how they view patient participation in treatment decision-making. Seventy disease-free cancer patients and
60 oncologists (surgical, radiation, and medical) were interviewed about their role preferences using the Control Preferences Scale
(CPS) and about their views on patient participation using closed- and open-ended questions. Almost all participants preferred
treatment decisions to be the outcome of a shared process. Clinicians viewed participation more often as reaching an agreement,
whereas 23% of patients defined participation exclusively as being informed. Of the participants, X81% thought not all patients are
able to participate and X74% thought clinicians are not always able to weigh the pros and cons of treatment for patients, especially
not quality as compared with length of life. Clinicians seemed reluctant to share probability information on the likely impact of
adjuvant treatment. Clinicians should acknowledge the legitimacy of patients’ values in treatment decisions. Guidelines should
recommend elicitation of patient values at specific decision points.
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Both clinicians and researchers have commented on the need to
involve patients in treatment decision making, especially when a
patient presents with a serious illness, different treatment options
exist, the gains of treatment should be weighed against possible
adverse effects, or outcomes are uncertain (Guadagnoli and Ward,
1998; Charles et al, 1999b; Robinson and Thomson, 2001).
Involving patients in treatment-related decision making is in line
with the increasingly acknowledged patients’ right to autonomy
and self-determination. The need to involve patients is supported
by evidence that physicians do not have the ability to adequately
judge patients’ values for outcomes of care (Cotler et al, 2001;
Montgomery and Fahey, 2001; Brothers et al, 2004; Stalmeier et al,
2007).
Treatment in oncology is often guideline-based, at least in the
Netherlands. Clinicians may access up-to-date information on
nationwide guidelines in oncological and palliative care through
http://www.oncoline.nl, a publication of the Dutch Association
of Comprehensive cancer centres (http://www.ikcnet.nl). In the
guideline development process, trade-offs between expected
benefits and side effects are almost exclusively made by clinicians,
not by patients. Also, these trade-offs are usually not made explicit
to patients. If patient values are to be incorporated in treatment
decision making, which seems especially relevant in decisions
on adjuvant treatment, this requires patients to participate in
the consultation and voice their values. There is considerable
uncertainty about what patients and clinicians understand by
patient participation (Guadagnoli and Ward, 1998). This study was
set up to assess what role oncologists and cancer patients prefer in
deciding about cancer treatment, and how they view patient
participation in treatment-related decision making. Earlier studies
have assessed decisional role preferences, but these are of limited
interest to situations where treatment choices are mostly guideline-
driven.
MATERIALS AND METHODS
Study population
Participants were disease-free rectal cancer patients who had
participated in a study assessing rectal cancer treatment prefe-
rences (Pieterse et al, 2007). For that study, a stratified random
sample was selected from patients who had participated in a
multicenter trial assessing the benefit of adding preoperative
radiotherapy (PRT) to total mesorectal excision surgery between
January 1996 and December 1999 (Kapiteijn et al, 2001).
Stratification was carried out to include equal numbers of patients
from both treatment groups as well as those who were reported to
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ssuffer from side effects at follow-up in both groups. A total of 94
eligible patients were approached. Of these, four patients could not
be reached and nine had other types of cancer or recurrent disease
and were excluded. Of the remaining 81 patients, 70 (86%) agreed
to participate. Reasons for refusal were the psychological burden
(N¼8), physical burden (N¼1), time investment (N¼1), or
unknown (N¼1).
For the treatment preference study, we aimed further to include
60 oncologists specialised in gastroenterology. We predominantly
aimed for surgical and radiation oncologists, as these specialties
are most involved in primary rectal cancer treatment. Seventy
eligible oncologists were randomly selected from surgeons,
radiotherapists, and medical oncologists involved in the
Simply Capecitabine in Rectal cancer after Irradiation Plus TME
(SCRIPT) trial and were approached. Three clinicians could not be
reached. Sixty (86%) oncologists agreed to participate (25 surgical,
25 radiation, and 10 medical). Reasons for refusal were time
constraints (N¼4), considering participation not meaningful
(N¼1 medical oncologist), being retired (N¼1), or unknown
(N¼1).
Procedure
Eligible participants were informed about the study by letter and
then asked by phone whether they agreed to participate. One of
two trained interviewers (AHP and MCMB-T) conducted indivi-
dual face-to-face interviews following a strict protocol. Interviews
were held at home (patients) or at the institution (oncologists). All
patients gave written informed consent at the start of the interview.
Interviews with clinicians were audiotaped with their permission.
Prior to the interview, sociodemographic, disease- (patients) and
work- (oncologists) related data were collected using a self-
administered paper-and-pencil questionnaire. The medical ethical
board of the Leiden University Medical Centre approved the study.
Participants were included between February and August 2006.
Interviews
We started the interview by assessing role preferences in treatment
decision-making using the Control Preferences Scale (CPS)
(Degner and Sloan, 1992). The CPS was devised to assess the
degree of control an individual wants to assume when decisions
are being made about a specific medical treatment (Degner et al,
1997b). It has been widely used in previous studies of cancer
patients (Rothenbacher et al, 1997; Wallberg et al, 2000; Mallinger
et al, 2006). We started out with this measure to help participants
think about participation in decision making. Patients especially
may never have thought about such issues. We asked participants
to focus on the hypothetical decision whether or not to undergo
PRT, had they presently been diagnosed with rectal cancer
(patients), or were they seeing a patient diagnosed with rectal
cancer (oncologists). The decision was not familiar to patients, as
they had been randomised to receive either PRT or not at the time
they were actually treated. Notably, we had not informed patients
about benefits and side effects of PRT.
The CPS consists of five cards, each of which portrays a different
role in treatment decision making using a statement. The roles
ranged from (A) the patient deciding on PRT, through (C) the
individual making the decision jointly with the physician (or
patient), to (E) the physician making the decision about PRT
(Figure 1). Participants were presented with a series of paired
comparisons of roles until the preferred role was established,
following the same procedure as Davey et al (2004). The statements
thus indicate a preference for an active (A and B), collaborative
(C), or passive (D and E) patient role in treatment decision
making.
Participants were then asked a set of closed questions relating
to the desirability of patient participation and to the weighing of
pros and cons of treatments (Table 1). Clinicians were asked
whether they would offer the option of an adjuvant treatment that
cures an additional 1–5% patients, but with a clinically relevant
risk of side effects in patients treated with that adjuvant treatment
(the absolute numbers and the nature of the treatment and
side effects were not further specified). The example was chosen
as a general case for current adjuvant treatments in cancer
care. Clinicians were further questioned about their preference
regarding the role of patients in the formulation of treatment
guidelines. Participants were asked to explain their answer
following each question. The interviewers noted participants’
answers on paper.
Coding
A random selection of five taped clinician interviews was used to
compare the recorded explanations with the paper notes taken
during the interview. This showed that main themes had not been
missed on paper.
Answers to the open-ended questions were categorised. Each
of the interviewers read a different random selection of five
patient interviews and separately developed an initial list of
codes intended to reflect the various views in participants’
responses. The interviewers compared their list of codes and
decided on a definitive set of codes and subheadings. In coding
oncologists’ answers, additional codes were decided on as needed.
Both interviewers then coded all participants’ explanations,
reviewed their coding, and resolved disparities. Participants’
answers could be categorised into one or more categories (see
Appendix A), depending on the number of reasons they
nominated. Answers were not categorised if they reiterated a
previous ‘yes’ or ‘no’ answer to the closed-ended question, if it was
open to interpretation, or if it did not refer to the question but
went beyond.
Control preferences in deciding about PRT
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Figure 1 Patients’ (N¼70) and clinicians’ (N¼60) control preferences
in deciding about preoperative radiotherapy (PRT). Note: Phrasing of
control preferences roles in patient interviews: (A) I prefer to make the
decision about my treatment; (B) I prefer to make the decision about my
treatment, after seriously considering my doctors’ opinion; (C) I prefer that
my doctor and I make the decision about my treatment jointly; (D) I prefer
that my doctor makes the decision about my treatment, after seriously
considering my opinion; (E) I prefer to leave the decision about my
treatment to my doctor. Phrasing of control preferences roles in clinician
interviews: (A) I prefer to leave the decision about treatment to my patient;
(B) I prefer that my patient makes the decision about treatment, after
seriously considering my opinion; (C) I prefer that my patient and I make
the decision about treatment jointly; (D) I prefer to make the decision
about treatment, after seriously considering my patient’s opinion; (E) I
prefer to make the decision about treatment.
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sAnalysis
Descriptive statistics (frequencies and percentages) were used to
describe sociodemographic, disease- (patients) and work- (oncol-
ogists) related data, role preferences, and the answers to the
closed- and open-ended questions. Using Fisher’s exact or w
2 tests,
as appropriate, proportions of patients and clinicians were
compared on their answers to the closed-ended questions and on
how often their explanation fell into one of the coding categories.
Bivariate associations between participants’ characteristics and
role preferences (active, collaborative, and passive patient role)
and responses to question 1 (Table 1) were assessed using t-tests,
ANOVA, Kendall’s t-correlation, w
2 tests, and Fisher’s exact tests.
Significance testing was done two-sided at a¼0.05.
RESULTS
Participants
Forty-eight male and 22 female patients participated. They were
aged 64 years on average (s.d.¼9.4; range: 41–84) at the time of
the interview and had been treated for rectal cancer 6–10 (M¼8;
s.d.¼1.0) years ago. Among those responding to demographic
questions, 31 (45%) patients had completed 9 years or less of
education, 23 (33%) 10–12 years, and 15 (22%) 13 years or more.
All patients had undergone surgery and 38 (54%) had also been
treated with PRT.
All surgeons as well as 14 out of 25 radiation and 9 out of 10
medical oncologists were male. The clinicians were between 35 and
62 years old (M¼48, s.d.¼7.3). Time since specialisation was 13
years on average (s.d.¼8.1, range, 1–31) and was not significantly
different according to specialty.
Control preferences scale
Figure 1 depicts participants’ preferences regarding their role in
the decision about PRT in the treatment of rectal cancer. Except
for eight (11%) patients who preferred to leave the decision to their
clinician, all participants would prefer both the patient and the
clinician to share in that decision.
There was a trend (P¼0.05) for patients’ and clinicians’
preferences over the active, collaborative, and passive patient
Table 1 Participants ´ answers to the closed-ended questions
Question
Desirability of patient participation
1. Do you think that cancer patients should be involved in decisions
regarding their treatment?
b
0% 20% 40% 60% 80% 100%
Patients (n=69)
Clinicians (n=60)
2. If so, do you think all patients are able to be involved in deciding
about their treatment?
c
0% 20% 40% 60% 80% 100%
Patients (n=60)
Clinicians (n=57)
3. If a patient does not want to be involved in deciding about
treatment, do you think that physicians should nevertheless try to
involve their patient in deciding about treatment?
0% 20% 40% 60% 80% 100%
Patients (n=70)
Clinicians (n=59)
Benefits and side effects of treatments
4. In deciding about treatment, one looks at advantages and
disadvantages of various options, among other things. Do you think
that physicians are always able to determine how these advantages
and disadvantages weigh for a patient?
0% 20% 40% 60% 80% 100%
Patients (n=70)
Clinicians (n=60)
5. If the decision is about quality vs length of life, do you think that
physicians can always decide for patients how these should be
weighed?
0% 20% 40% 60% 80% 100%
Patients (n=69)
Clinicians (n=60)
aNumbers do not add up to 70 (patients) or 60 (clinicians) due to missing data.
bOne physician qualified a ‘yes’ answer by adding ‘to a limited extent’; we counted that answer as
a ‘no’.
cThis question was asked to those participants who answered ‘yes’ to the first question, ie, to 66 patients and 57 clinicians. Numbers do not add up to 66 in patients due to
missing data.
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sroles to differ. The clinicians preferred in majority the collabora-
tive role (73%), whereas patients’ role preferences were more
equally spread out over the three levels of involvement.
There was a significant association (P¼0.03) between a lower
educational level in patients and their preference to relinquish
decisional control to their clinician. Also, preferences of male
compared with female patients were significantly (P¼0.04)
different, with preferences of male patients being more equally
distributed over the decisional roles. Clinicians’ specialty was
significantly (P¼0.01) related to their role preferences. Medical,
radiation, and surgical oncologists preferred the clinician to decide
mainly in increasing proportions (10, 20, and 24%, respectively).
No significant associations were found between decisional role
preferences and participants’ age, patients’ past treatment with
PRT (yes/no), or clinicians’ time since specialisation.
Desirability of patient participation in treatment-related
decision making
Table 1 shows that overall almost all patients (N¼66, 96%) and
clinicians (N¼57, 95%) thought that cancer patients should be
involved in decision making regarding treatment (question 1).
Responses did not significantly differ according to patients’
gender, educational attainment, or past treatment, nor to
clinicians’ specialty.
The patients and clinicians did not significantly differ in the
frequency with which they explained their answer by referring to
patient autonomy (patients: 44%, clinicians: 46%), the need to
inform patients (patients: 39%, clinicians: 35%), and to openness
in patient–clinician communication (patients: 14%, clinician: 5%).
A significantly larger proportion of clinicians than patients (23 vs
5%; Po0.01) referred to the outcome of the decision process, in
that patients and clinicians should reach an agreement about
treatment and/or that a participating patient is more motivated
and therefore endures the treatment better. There was a trend for
clinicians to refer more often to their responsibility and expertise
(25 vs 12%; P¼0.10). Eight (14%) clinicians compared with none
of the patients referred to the necessity to comply with the
informed consent procedure, and for six of the eight this was their
sole explanation. Of the 66 patients, 15 (23%) motivated their
response only as the need for patients to be informed, compared
with none of the clinicians.
Most participants (patients: N¼51, 85%; clinicians: N¼46,
81%) thought that not all patients are able to participate in such
decision making (Table 1, question 2). There was a trend (P¼0.07)
for patients’ and clinicians’ responses to differ if we took the
patient (male, 71 years old, with 13 years or more education, and
irradiated prior to surgery) into account who did not have an
opinion on the issue. If we discard this participant, patients’ and
clinicians’ responses did not significantly differ.
There was a trend (P¼0.10) for patients (22%) to refer more
often to patients’ psychological inability (not further specified),
when compared with clinicians (9%). Patients (43%) and clinicians
(33%) referred in similar proportions to emotional incapacities,
including patients’ anxiety or lack of confidence. A significantly
larger proportion of clinicians compared with patients (59 vs 22%;
Po0.001) referred to cognitive deficiencies, in that patients may
not grasp the information provided and especially have difficulties
with understanding the risks involved. Clinicians tended also to
refer more often to co-morbidity, including dementia and
psychiatric disorders, when compared with patients (28 vs 12%;
P¼0.07). Other explanations related to sociodemographic factors,
including age, social support, and religion (patients: 12%,
clinicians: 20%) and the novelty and complexity of the decision
situation for patients (patients: 6%, clinicians: 4%).
A large majority (patients: N¼55, 79%; clinicians: N¼41, 69%)
of participants indicated that clinicians should try to involve
patients in decisions about their treatment, even if the patient is
reluctant to be involved (Table 1, question 3). Patients’ and
clinicians’ responses significantly differed (P¼0.04) if we take into
account the two male respondents (70 and 75 years old, 9 years or
less education, and irradiated preoperatively) who did not have an
opinion on the issue. If we discard their response, patients and
clinicians did not significantly differ in their opinion on the
involvement in treatment decision making of reluctant patients.
Participants justified their conviction by referring to patient
responsibility (patients: 18%, clinicians: 7%) and the temporary
nature of patient’s reluctance (patients: 7%, clinicians: 2%). Others
(patients: 13%, clinicians: 15%) viewed it as part of the clinician’s
task. Moreover, participants (patients: 46%, clinicians: 56%) often
referred to the manner in which physicians may proceed, such as
by providing information, reassuring the patient, or involving
significant others of the patient. Several participants (patients:
16%, clinicians: 17%) stated that the clinician should try to involve
a reluctant patient only within reason. In contrast, four patients
compared with none of the clinicians considered that a clinician
should try to involve a patient to the utmost. Participants’ reasons
for not trying to involve a reluctant patient referred to respect for
the patient’s wish not to participate. Participants indicated,
moreover, that in such circumstances a clinician should adopt
the role of providing information (N¼5) or involving significant
others of the patient (N¼1).
Weighing benefits and side effects of treatments
A large majority of patients (N¼52, 74%) and clinicians (N¼49,
82%) thought that clinicians are not always able to weigh the pros
and cons of treatment for their patients (Table 1, question 4).
Participants referred to individual differences in patients’
experience and the acceptance of treatments (patients: 39%,
clinicians: 35%), the lack of skills and/or the subjective stance of
the clinician (patients: 21%, clinicians: 29%), and insufficiencies in
the dialogue between patients and clinicians (patients: 27%,
clinicians: 29%). Participants thinking that a clinician always has
this ability (patients: N¼16, 23%; clinicians: N¼11, 18%), in
contrast, referred mostly to clinicians’ skills and responsibility
(patients: 81%, clinicians: 55%). Others referred to the clinician
knowing patients sufficiently (patients: 13%, clinicians: 27%). One
patient (7%) explained it by the patient’s trust in the clinician.
Overall, even higher proportions of participants (patients:
N¼61, 88%; clinicians: N¼52, 87%) did not think that clinicians
can always weigh the value of quality compared to length of life
accurately for individual patients, even though this may be viewed
as a specific case of weighing the pros and cons of treatment
mentioned above (Table 1, question 5).
Participants related clinicians’ lack of insight in patient values
often to individual patient differences. Patients did so significantly
more often than clinicians (patients: 66 vs clinicians: 42%;
P¼0.02). A significantly larger proportion of clinicians compared
to patients underlined the importance of dialogue, referring to the
need for patients to bring their values forward in the interaction
with the clinician (patients: 10 vs clinicians: 35%; Po0.01). Other
participants (patients: 7%, clinician: 10%) referred to limitations
resulting from physicians’ emotions, experience, and subjective
stance.
When asked explicitly about an adjuvant treatment that cures an
additional 1–5% patients at the expense of a clinically relevant risk
of side effects, a significant minority (17%) of clinicians would not
even propose the treatment to their patient. None of the remaining
83% clinicians would prescribe that treatment without discussing
it first with their patient. Of them, half (54%) would tell patients
the absolute probabilities of benefits and side effects and other
half (46%) would not. Moreover, a majority (63%) of clinicians
indicated that in their opinion, patients should be involved in the
formulation of treatment guidelines. A significant minority (37%)
was opposed to patient involvement at that stage.
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sDISCUSSION
The results from this study suggest that both in case of a specific
adjuvant treatment decision situation and more generally, a large
majority of treated cancer patients and clinicians prefer the
decision to be the outcome of a shared decision-making process.
Our results support previous research in newly diagnosed cancer
patients (Degner et al, 1997a), in palliative cancer care patients
(Rothenbacher et al, 1997), and in a healthy population (O’Donnell
and Hunskaar, 2007) that a higher educational attainment is
associated with a preference for a more active role in decision
making. Our finding that gender may affect decisional role
preferences adds to the evidence that is, as of yet, inconclusive
(reviewed by Hubbard et al, 2008). Further assessments are needed
before firm conclusions can be drawn. Our results on surgical
oncologists preferring to a greater extent that the clinician mainly
decides on treatment compared with radiation and medical
oncologists may seem to diverge from Charles et al’s (2003)
results. They found breast cancer surgeons to agree more often
than radiation and medical oncologists to the statement that
patients and physicians agreeing together to the treatment to be
given, to be important to a shared decision-making process.
However, surgeons’ understanding of a shared process may differ
from their preferences regarding actual decision-making in the
clinic. Other determinants of decisional role preferences could not
be traced.
Up to one-fifth of the patients and one-third of the clinicians felt
that reluctant patients need not be involved in the decision
making, referring to respect for the patient’s attitude. Bearing in
mind that clinicians are not accurate in judging patient values for
the outcome of care (Cotler et al, 2001; Montgomery and Fahey,
2001; Brothers et al, 2004; Stalmeier et al, 2007), it seems in these
cases critical to ascertain that the patient persists in preferring
non-involvement.
Importantly, these results do not as such shed light on whether
patients and clinicians actually agree on how patient involvement
should take place. The participants provided a variety of
explanations for their opinions on participation. Clinicians more
often than patients defined patient participation in terms of
clinician–patient communication, namely reaching an agreement
about treatment. Some clinicians compared to none of the patients
explained the need for patient participation in terms of the need to
comply with the informed consent procedure. For a significant
minority (10%) of clinicians, this was their only motivation. It is
unclear how these clinicians view the legal definition of patient
participation and whether it goes beyond informing patients and
asking them for consent to treatment plans that clinicians have
proposed.
There is no agreement on the definition of shared decision
making in the literature (Makoul and Clayman, 2006; Moumjid
et al, 2007). However, essential elements incorporated in all
prominent cited models of shared decision making include not
only the presentation of options but also the discussion of patient
values (Makoul and Clayman, 2006). Accordingly, the focus of
common definitions of shared decision making is both on infor-
mation exchange between physician and patient and the involve-
ment of both parties in the decision made (Moumjid et al, 2007).
As a result, patient participation presupposes that both clinicians
and patients have responsibilities, which stands in sharp contrast
to patients only being informed. Strikingly, a significant minority
of patients explained participation in decision making exclusively
in terms of being informed. Our finding is in accord with evidence
from a qualitative study including 41 patients diagnosed with
colorectal cancer. Patients in that study reported to perceive that
there was a ‘right’ decision to be made and that doctors would
make the right decision for them (Beaver et al, 2005). Several other
studies have also shown that patients more often prefer to receive
information than to actually participate in decision making
(Blanchard et al, 1988; Ende et al, 1989; Nease and Brooks, 1995;
Benbassat et al, 1998). Clearly, not all patients want to be involved
(Davison et al, 1995; Beaver et al, 1999; de Haes, 2006). Schwartz
(2004) has even questioned the superiority of patient autonomy.
Making choices may be a burden rather than a good option. By
choosing one option, the patient dismisses the advantages of the
options that are not selected, and this implies loss. Similarly,
anticipated and post-decision regret may be at stake (de Haes,
2006). None of the clinicians, in contrast, appeared to agree that
informing a patient is sufficient to consider the patient involved in
the process. This finding is in line with results of Charles et al
(2003), showing that only few physicians would define shared
decision making in terms of information exchange alone.
Where clinicians and patients wish to share in the decision-
making process, patients should voice their values during their
interaction with their clinician. However, patients may feel inti-
midated by their doctor because of the power differential (Bryant
et al, 2006), and therefore refrain from participating (Guadagnoli
and Ward, 1998; Roter et al, 2007). Physician use of supportive
communication was found to be essential to facilitate patient
involvement (Street et al, 2005) and physicians’ explicit encourage-
ment of patient participation may foster patient participation in
medical decision making (Fraenkel and McGraw, 2007).
More than 80% of patients and clinicians doubted as to all
patients’ ability to participate in treatment decision making, even
though almost all participants considered it necessary. Clearly,
participants’ doubts as to patients’ capacities could point to the
exceptional cases of emotional disturbance or cognitive deficien-
cies. But the limitations that participants stated could apply to any
ordinary patient, not the isolated case. Patients and clinicians often
nominated emotional barriers. Indeed, distress may hamper
patients’ capacity to process information (McHugh et al, 1995;
Erblich et al, 2003). Clinicians more often than patients further
viewed cognitive limitations in patients as a barrier. Limited
educational attainment and literacy skills have been shown to
relate to difficulties in understanding and recalling complex
medical information (Williams et al, 2002). As already suggested
by some of the patients and clinicians in this study, clinicians may
find ways to involve the more common patients, such as by
addressing their fears, simplifying the information, or repeating it
to facilitate its processing. Limited skills in patients to understand
medical information should be an important motivation for
clinicians to explain the information in even more simple
language, take time to repeat the relevant details and to check
understanding, and supply reference materials. Importantly,
where inability is related to feelings of intimidation or lack of
encouragement, clinicians could help patients to overcome
patients’ hesitations.
Interestingly, none of the participants in our study suggested
time constraints as a barrier to patient involvement. In Fraenkel
and McGraw’s (2007) study, time during medical encounters was
nominated as an essential element to enable patients to become
informed and to process information. Results in patients with
heterogeneous cancers suggest though that clinical encounters
need not be lengthened if the clinician proactively addresses
patient questions (Brown et al, 2001).
Patients and clinicians seemed to agree that clinicians need
patient input to assess accurately how the individual patient
weighs pros and cons of treatment alternatives. Up to one-fifth of
patients and almost one-third of clinicians made reference to
clinicians’ subjective stance. They recognised that the expertise of
clinicians does not exist in a vacuum but is embedded in their
interpretation of the situation and their perception of the patient.
Interestingly, if pros and cons are specified as quality vs length of
life, participants agreed even more strongly to clinicians’ limita-
tions in this regard. In their explanations, patients emphasised
individual patient differences. Clinicians underlined patients’ role
in terms of the need for clinicians to receive patient input in order
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sto assess accurately how an individual patient weighs risks and
benefits of treatments. In practise, this standpoint implies that
clinicians are willing to inform patients about risks and benefits of
treatments, and maybe to a larger extent than they routinely do.
In particular, this requires the use of precise vocabulary so as to
facilitate patient recall of the discussion of relevant treatment
options (Keating et al, 2003) and guarantee the necessary
specificity to help patients estimate the impact of the treatment
on their lives (Davidson et al, 2007). This perspective also requires
clinicians to help patients to bring their values forward. Evidently,
clinicians should then be prepared to acknowledge the legitimacy
of patients’ values in treatment decisions. Also, patients should
then accept to share the responsibility for the treatment decision
(Charles et al, 1999a).
A significant minority of clinicians indicated that they would
decide against offering an existing treatment if the small probability
of extra benefit would go hand in hand with a large probability of
side effects. This is what may be termed a physician’s silent decision
(Whitney and McCullough, 2007) and may be justified by
considerations of (lack of) clinical utility. Yet, clinicians’ opinion
about the clinical utility in this case varied. Also, almost half of the
clinicians who would offer the treatment, would not state the
absolute probabilities. These results are in line with those from
Ravdin et al (1998). Their study showed that women with breast
cancer often are not given quantitative estimates of the magnitude of
probable benefit and toxicity of adjuvant therapy. Not stating the
probably impact of adjuvant therapy or using probability words
instead of numbers may result in patients understanding poorly the
trade-offs in benefits and side effects. Indeed, the breast cancer
patients in Ravdin et al’s study overestimated their risk of early
relapse and the effectiveness of their adjuvant therapy, even though
they were younger and better educated than the average woman
with breast cancer. For patients to be active, informed participants
in the treatment-related decision-making process, probability
information on benefits and risks of treatment alternatives is of
critical value. It is questionable to what extent a patient can actually
think about the pros and cons of treatment if the clinician is not
willing to share relevant evidence.
Our results suggest that at least some clinicians support the
involvement of patients in the formulation of guidelines. Alter-
natively, guidelines may explicitly prescribe the need to elicit
patient views at specific decision points. Dutch guidelines on
cancer treatment (www.oncoline.nl) including for example the
recently updated guideline for rectal cancer and the one for breast
cancer, include the recommendation that clinicians should
extensively inform their patients about benefits and side effects
of treatment alternatives. This recommendation underlines the
need for clear information but does not go as far as stating that
patient values for outcomes of care should explicitly be discussed
when a treatment decision needs to be made, nor that treatment
advice could vary, according to patient values. Yet, in order to
obtain the best achievable care for individual patients, treatment
choice should vary according to clinical circumstances and to
patient values (Hlatky, 1995). In the process of involving patients
further than only informing them, patients may increasingly prefer
to be treated in other ways than standard treatment. Guidelines
may be explicit on this point and include the remark that given
particular patient values, deviating from consensus treatment may
be acceptable.
In conclusion, our results run counter to guideline-based
treatment of patients, in cases where clinicians’ treatment advice
is not based upon individual patient values. A majority of
clinicians and patients in this study were in favour of clinicians
and patients reaching an agreement on treatment. They held the
conviction that clinicians cannot accurately predict how pros and
cons of treatment weigh for their patients. Clinicians should
inform patients extensively about treatment options and should
acknowledge the legitimacy of patients’ values in deciding about
treatment. Ideally, treatment guidelines should include the
recommendation that patient values about treatment benefits
and side effects should explicitly be elicited at the time a treatment
decision needs to be made.
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Appendix A Coding scheme
Question Heading Subheading Examples of utterances coded
1. Do you think that cancer patients should be involved in decisions regarding their treatment?
a
Conditions for involvement Information Being able to understand information about alternatives; right to receive information
Patient-clinician
relationship
Clinician’s honesty; patient’s trust in clinician; clinician’s clarity of information
Decision There is a choice to be made
Roles in decision-making process Patient Patient autonomy; patient chooses what he/she considers as quality; patient carries
responsibility; patient thinks along
Clinician Clinician has the expertise; clinician advises; clinician is responsible
Outcome of decision-making
process
Patient and clinician reach agreement; motivated patient endures the treatment better
Legal obligation Informed consent
procedure
Need to comply to the informed consent procedure
2. If so, do you think all patients are able to be involved in deciding about their treatment?
b
Psychological inability
c —
Emotional barriers Patient is too anxious; patient is emotionally unstable; patient lacks confidence
Cognitive barriers Patient has limited intelligence; patient has difficulties with appraising risks; patient does
not understand the information
Socio-demographic factors Patient stems from an older generation; patient lacks social support; patient holds
particular religious beliefs
Co-morbidity Dementia; intellectual disability; psychiatric disorder
Complex situation Patient is unfamiliar with decision situation; information is complex
3. If a patient does not want to be involved in deciding about treatment, do you think that physicians should nevertheless try to involve their patient in deciding about treatment?
d
Reason why Patient: Temporary
evasive behaviour
Patient feels panicky; it is important to help prevent regret in patient
Patient: Responsibility Patient is (also) responsible; patient has to live with the consequences; patient is
autonomous
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Question Heading Subheading Examples of utterances coded
Clinician It is clinician’s task; clinician needs patient agreement
Patient-clinician
relationship
Creates mutual trust
Clinician’s devotion to involve
patient
To the utmost Clinician should try to involve patient to the utmost
Within reason Clinician should try to involve patient within reason
Respect patient’s wish Clinician should respect patient’s wish not to participate
Manner in which Clinician gives information; clinician reassures the patient; clinician takes time; clinician
involves significant others of patient; clinician gains patient’s trust
4. In deciding about treatment, one looks at advantages and disadvantages of various options, among other things. Do you think that physicians are always able to determine how
these advantages and disadvantages weigh for a patient?
e
5. If the decision is about quality vs length of life, do you think that physicians can always decide for patients how these should be weighed?
Yes, the starting point is they Patient Patient trusts the clinician; patient does not understand the situation well enough
Clinician Clinician has the expertise; clinician is responsible; clinician has the ability to estimate
patient values
Patient-clinician
relationship
Good communication; clinician knows the patient well enough
No, the starting point is the y Patient Individual patients differ too much from one another; patient makes own decision;
patient knows best; patients ´ experience with health or health care differ; patients differ
in their acceptance of treatments
Clinician Clinician has own subjective stance; clinician cannot infer importance for patient;
clinician brings in own emotions
Patient-clinician
relationship
Clinician does not know patient well enough; clinician and patient need to consult
together; patient needs to share own values with clinician
aThe participants’ explanations to this question were only coded in those agreeing to patient involvement.
bThe participants’ explanations to this question were only coded in
those agreeing to patient involvement (question 1) and disagreeing to question 2.
cThis category includes references to psychological inabilities in patients that participants did not
further specify.
dThe participants’ explanations to this question were coded both in those answering ‘yes’ and ‘no’ to the question.
eCoding categories for questions 4 and 5 were
identical.
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